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1. Introduction 
Neurological complications may occur in 30 to 60% of the patients undergoing organ 
transplantation, especially liver and bone marrow (Padovan et al. 2000). Because of the 
constantly changing protocols regarding the transplantation procedure and the subsequent 
immunosuppression required for the prevention of graft rejection and graft versus host 
disease, the nature of the neurologic complications has changed over time. 
Recipients of solid organ or bone marrow cell transplants are at risk of life-threatening 
neurological complications including encephalopathies, seizures, brain infections and 
malignancies, stroke, central pontine myelinolysis and neuromuscular disorders. Many of 
these disorders are linked directly or indirectly to the immunosuppressive therapy. 
However, they may also result from graft versus host disease, from pretransplantation 
radiation or chemotherapy, and from injuries induced during surgery and intensive care 
unit(ICU) stay. In rare cases neuroinfectious pathogens may be transmitted with the 
transplanted tissue. Though most of the neurological complications occur disrespectful of 
the transplanted organ, transplant-specific complications also exist. Heart and pulmonary 
transplants are frequently associated to cerebral hypoxia, ischemia and bleeding. Bone 
marrow transplant is commonly associated with prolonged thrombocytopenia that may lead 
to catastrophic cerebral haemorrhage (Bashir 2001). 
In spite of the advances that have been made in the management of transplanted patients, 
the so-called posttransplantation encephalopathy (PTE), a complex syndrome with various 
etiologies characterized especially by disturbance of consciousness, is still frequently 
observed. The spectrum of PTE is vast and changes along in relationship with the time that 
has passed since transplantation (see Table1). Metabolic disturbances (secondary to the 
underlying or associated systemic disease or iatrogenic), drug neurotoxicity (caused by 
immunosuppressant, but also by antibiotics or other drugs), disimmunity and opportunistic 
central nervous system infections are frequent PTE etiologies. Though commonly the 
encephalopathies with these etiologies are well circumscribed clinical entities, highlighting 
the diagnostic and therapeutic particularities arising from their occurrence in the 
posttransplantation setting is of great utility for the current clinical practice. Moreover, 
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encephalopathies of different etiologies may overlap in the same transplanted patient 
(Mathew and Rosenfeld 2007).  
The etiological diagnosis of PTE is challenging because the clinical presentation and the 
neuroimagistic findings lack specificity and the unique circumstances related to the 
underlying disease, the transplant procedure and the subsequent management may give rise 
to less typical presentations. Most clinical signs of PTE are nonspecific and do not reliably 
identify a particular etiology. Humoral or tissue samples are often required for definite 
diagnosis.  
The major clinical feature is impaired attention, but the clinical findings can range from 
subtle cognitive difficulties to delirium or coma. A characteristic abnormality is marked 
fluctuation in the level of consciousness. The motor signs are variable and include tremor, 
asterixis and multifocal myoclonus, the latter particularly involving the face and the 
proximal muscles. In the severely affected subjects decorticate and decerebrate posturing 
may occur. Computed tomography (CT) or magnetic resonance imaging (MRI) of the brain 
is mandatory when signs suggestive for diffuse or focal brain injury are present. If clinical 
examination shows no focal signs and brain MRI is normal, the most probable causes of the 
encephalopathy are systemic metabolic abnormalities or drug toxicity (commonly related to 
cyclosporine, tacrolimus or amphotericin-B). In postransplatation encephalopathic patients 
with normal MRI cytomegalovirus (CMV) infection should also be considered. In the setting 
of CNS signs and symptoms the electroencephalogram (EEG) is a useful investigation since 
it can identify diffuse non-specific slowing of the normal activity translating diffuse brain 
injury, and it can confirm the presence of non-convulsive seizures which may be difficult to 
differentiate from confusion or other mental status changes on clinical grounds only. The 
required laboratory investigations include complete blood count, coagulation studies, 
electrolyte panel, glucose, renal and liver function parameters and arterial blood gases. 
Assessment of the blood immunosuppressive drug levels should be performed when 
overdose may have occurred and blood and CSF cultures should be obtained when infection 
is suspected. 
Early  
posttransplantation period 
(first 30 days) 
Subacute 
posttransplantation period 
(1-6 months) 
Chronic 
posttransplantation period 
(>6 months) 
METABOLIC 
DISTURBANCES  
OPPORTUNISTIC 
INFECTION (SOLID 
ORGAN ALLOGRAFTS) 
OPPORTUNISTIC 
INFECTION (SOLID 
ORGAN ALLOGRAFTS) 
HYPOXIC-ISCHEMIC 
ENCEPHALOPATHY 
METABOLIC 
DISTURBANCES  
METABOLIC 
DISTURBANCES  
IMMUNOSUPPRESSIVE 
DRUG TOXICITY  
IMMUNOSUPPRESSIVE 
DRUG TOXICITY  
IMMUNOSUPPRESSIVE 
DRUG TOXICITY  
OPPORTUNISTIC 
INFECTION (BONE 
MARROW 
TRANSPLANTATION) 
  
Table 1. The time relationship with the transplant procedure of the common causes of PTE 
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The patient’s management should be centered on preventing further neurological injury, 
administering etiology-targeted therapy, and balancing the benefits and toxicities of the 
specific immunosuppressive agents used. Knowledge regarding the etiologies of PTE and 
their incidence in relationship with the posttransplantation period in which they occur is 
essential for the adequate medical approach (Mathew and Rosenfeld 2007). Without the 
objective of being exhaustive, the present chapter offers an updated overview on the subject. 
2. Encephalopathy related to the underlying disease  
In a significant number of cases the disease that imposed transplantation also predisposes to 
brain injury, some patients having a certain degree of encephalopathy when the transplant 
procedure takes place. Moreover, hyperacute, acute or cronic graft rejection may also lead to 
encephalopathy secondary to organ failure (but also, see ‘Rejection Encephalopathy’ below). 
Patients with end-stage cardiomyopathy may develop encephalopathy secondary to global 
cerebral hypoperfusion. 
Patients with chronic renal failure may develop pretransplant uremic encephalopathy and 
acute renal rejection encephalopathy (Brouns et De Deyn 2004). 
The patients undergoing liver transplant may continue to experience hepatic 
encephalopathy if the graft fails acutely and/or may suffer hypoxic ischemic brain injury. In 
the majority of cases the clinical picture is the expression of the intracranial hypertension 
caused by brain edema, i.e. the net increase in brain water that may occur in the cellular 
(cytotoxic edema) or interstitial (vasogenic edema) compartments of the brain. Toxic, 
metabolic, inflammatory and infectious humoral factors may play a pathogenic role in the 
development of brain edema. Therefore, measurement of arterial ammonia levels is 
important for estimating the risk for the development of intracranial hypertension. It has 
been reported that worsening of hepatic encephalopathy may precede the detection of 
bacterial infection by an average of 24 hours, so, is recommended that patients experiencing 
worsening of hepatic encephalopathy should be treated with empiric wide-spectrum 
antibiotics. In those with hepatic insufficiency the translocation of bacteria from the intestine 
to regional lymph nodes may be an important pathogenic pathway, but endovenous 
catheters are also important routes of infection. Acute hyponatremia can induce brain 
edema by itself, therefore electrolytes levels should be routinely checked (Londono et al. 
2006). 
Brain edema leads to impaired consciousness ranging from sleepiness to stupor and coma 
and correlates with severe encephalopathy. The presence of long tract signs, decerebrate 
posturing, alterations in pupillary reactivity, or abnormalities in oculovestibular reflexes are 
specific though not sensitive indicators of the presence of an increased intracranial pressure. 
Radiological detection of brain edema can provide useful information, but the sensitivity is 
low. For identifying the presence of intracranial hypertension, intracranial pressure 
monitoring is the most accurate tool. 
The therapeutic measures include treatment of the underlying disease and correction of the 
metabolic disturbances. Ammonia can be removed by dialytic methods. N-acetylcysteine 
administered over 3-days infusion may lead to a significant improvement in the survival of 
those with mild hepatic encephalopathy. The management of elevated intracranial pressure 
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includes correcting the patient's position, temperature, ventilation and hemodynamics and 
when present removal of the excessive fluid. Osmotic therapy (e.g. mannitol 0.25 to 2 g/kg 
as 20% solution IV over at least 30 minutes, administered not more frequently than every 6 
to 8 hours) is commonly administered. In selected cases forced hyperventilation (aiming a 
paCO2 lower than 25 mmHg), barbiturate coma, high dose indomethacin administration 
and bilateral decompressive craniectomy should be taken into consideration (Jantzen 2007).  
3. Cranial irradiation encephalopathy  
Cranial irradiation is commonly used before bone marrow transplantation. Encephalopathy 
related to cranial irradiation has been reported. The clinical picture is that of an acute 
encephalopathy characterized by fever, headache, nausea, somnolence and seizures. The 
cause is diffuse cerebral edema. The treatment comprises of corticosteroids administration. 
In those with hematologic malignancies, pretransplant cranial irradiation and intrathecal 
chemotherapy may also cause a delayed leukoencephalopathy, which may occur even 
several years after these procedures. 
4. PTE due to transplantation procedures 
Hypoxic-ischemic encephalopathy is a potential posttransplantation complication common 
to most of the transplant procedures. 
Hypoxia describes a reduction in oxygen supply or tissue utilisation, which leads to an 
increase in cerebral blood flow that aims at providing glucose to the brain and clearing toxic 
metabolites. 
Ischemia refers to a reduction in blood supply, which leads to decreased oxygen delivery, 
impaired clearance of the accumulating toxic cellular metabolites (lactate, H+, glutamate) 
and subsequent exacerbation of the pre-existent brain injury. Global cerebral ischemia is 
usually due to: cardiac arrest, profound hypotension associated with surgery, shock, sepsis, 
metabolic encephalopathy, prolonged hypoxia or hypoglycemia and severe anemia (Liang 
2000). Precaution should be taken to avoid the occurrence of these precipitating factors. 
Elevated cerebral metabolic rate may also play a role in the etiology of hypoxic-ischemic 
encephalopathy. Global cerebral ischemia quickly leads to impaired synaptic transmission 
and axonal conduction. The degree of neuronal susceptibility to the hypoxic/ischemic injury 
is not uniform within the brain, particularly vulnerable regions being the hippocampus, the 
neocortex, the reticular nucleus of the thalamus, the amygdala, the cerebellar vermis and 
some neurons in the caudate nucleus and pars reticulata of the substantia nigra. This 
different topographic susceptibility to ischemic injury seems to be caused by the specific 
properties of the neurons in those brain regions, and not by uneven circulation. An impaired 
cerebral oxygen supply may lead to transient or irreversible neurologic changes, depending 
on the severity of the initial insult and on the post-resuscitation management. 
The clinical picture of hypoxic ischemic encephalopathy consists of impaired consciousness 
ranging from coma to vegetative state or minimally conscious state and epileptic seizures. 
Generalised tonic-clonic seizures may be masked in the first days, due to sedation. Focal 
seizures may be restricted to blinking, eye deviations or small repetitive facial or limb 
movements, which can be easily overlooked. Multifocal generalised myoclonus 
(posthypoxic myoclonic status) may start immediately after injury, responds unsatisfactory 
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to medication and translates a poor prognosis. Focal myoclonus, action or startle sensitive 
(Lance-Adams syndrome), may appear in the first 24-48 hours after the injury, responds 
well to antiepileptic drugs (valproate, levetiracetam, clonazepam) and carries a favourable 
prognosis(Chabolla et al. 2003). 
The investigations required when facing hypoxic-ischemic encephalopathy include: 
Neurophysiological tests (EEG, somatosensory evoked potentials), which are valuable in 
assessing the diagnosis and prognosis. 
Imaging studies, which in the first days commonly show brain edema (hypodensity on CT 
or hyperintensity on MRI - DWI, FLAIR- localised in the cortical grey matter, basal ganglia 
and subcortical white matter). In the subacute phase there is progressive resolution of brain 
edema, normalisation of DWI, but persistence of cortical, basal ganglia and white matter 
hyperintensity on T2 and FLAIR images. Cortical laminar necrosis and boundary zone 
infarctions may also appear. 
The treatment should be adapted for each particular situation, but several approaches are 
commonly required. As mentioned above, if raised intracranial pressure is clinically 
suspected, several measures should be taken: adequate positioning of the head, 
osmotherapy (mannitol, hypertonic saline), controlled hyperventilation and metabolic 
control (fever, seizures, hypoglycaemia, hypokalemia). Systemic coagulopathy can occur, 
due to an increase in cytokines, so antithrombotic therapy should be given. For the patients 
in coma, hypothermia should be tried, as it increases the chances for a good outcome, if the 
possible complications are avoided (i.e. cardiac arrhytmias, sepsis, hypotension during 
rewarming, renal failure, hypokalemia). 
The outcomes of hypoxic-ischemic brain injury include death, coma, vegetative state (VS), 
minimally conscious state (MCS), severe neurological or cognitive deficits, with chronic 
dependence on nursing care or, in some cases, recovery. The factors that correlate with 
worse prognosis are: duration of coma over 6 hours, absence of spontaneous limb 
movements or localisation to painful stimuli in the first hours, prolonged loss of pupillary 
responses, ocular abnormalities (e.g. sustained conjugate eye deviation, up- or downbeat 
nystagmus, ping-pong gaze, periodic alternating nystagmus), myoclonic seizures, absent 
reflexes of lower cranial nerves (cough and gag reflexes). Biomarkers that may predict 
outcome have been searched. So far, the only one that appears to be related to a poor 
prognosis seems to be neuron specific enolase (NSE), if it rises over 80ng/ml in the first days.  
Among the types of transplant, lung transplantation is associated with increased risk of 
hypoxic-ischemic encephalopathy. A particular situation is that of heart transplantation 
which has similar neurological complications as other open-heart procedures, including 
encephalopathy. The manifestations of the perioperative cerebral injury include ischemic 
(or, less commonly, hemorrhagic) stroke, encephalopathy and neurocognitive dysfunction 
occurring in the first month after surgery. Brain injury secondary to cardiac surgery is 
primarily ischemic. The etiology of ischemic brain injury secondary to cardiac transplant 
includes: 
1. Cerebral embolism: cerebral macroembolism arising from the ascending aorta causes 
stroke, while cerebral microembolism causes encephalopathy and neurocognitive 
dysfunction; microemboli are either gaseous or particulate. 
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2. Cerebral hypoperfusion: induces injury caused by the combination of systemic 
hypotension and cerebral venous hypertension (traction on the superior vena cava), 
occuring during off-pump surgery. 
3. Atherosclerosis of the aorta: atherosclerotic lesions injury during surgery can result in 
emboli and may expose lipidic prothrombotic material, which promotes thrombus 
formation postoperatively. On the other hand, atherosclerosis of the ascending aorta is a 
marker for severe atherosclerosis of the cerebral arteries, which prones to cerebral 
injury during hypoperfusion. 
4. Perioperative anemia reduces cerebral oxygen delivery and/or causes increased 
cerebral blood flow, increasing the number of potential emboli.  
5. PTE related to the immunosuppressive medication 
Immunosupresive therapy is required in all transplanted patients for the prevention of graft 
rejection and graft versus host disease. Commonly used drugs include calcineurin 
inhibitors, corticosteroids and biological agents. It is widely recognized that the 
immunosuppressive therapy is associated with an increased incidence of sepsis (and thus of 
sepsis encephalopathy) and of central nervous system opportunistic infections, both of 
which are briefly discussed in separate sub-chapters. The literature is abundant in case 
reports of encephalopathy occurring in the absence of sepsis or neuroinfections. As detailed 
further on, these encephalopathies appear to be specifically related to several drugs. Their 
evolution is typically favourable, providing the offending drug is stopped. It is important to 
note that even if metabolic disturbances or other causes that may explain the 
encephalopathy are identified, the blood levels of the potential neurotoxic drugs that the 
patient is receiving should be assessed. 
Certain particularities in respect with the organ being transplanted have been reported. 
The patients undergoing liver transplantation commonly have an advanced stage of the 
disease resulting in immunodepression and coagulopathy (Watt et al. 2010). Disrespectful of 
the technique used, the surgical procedure required by liver transplantation is very complex 
and has high risk of blood loss or massive fluid shifts. In the days following the transplant, 
the engrafted liver releases immunologically active cells (T-cells, macrophages, stem cells), 
which can react with the host immune system, already affected by the preexistent liver 
failure and by the immunosuppressive medication. Liver transplanted patients commonly 
develop PRES related to calcineurin inhibitors administration early after transplantation and 
usually have associated favouring factors such as serious bacterial infection, organ rejection 
or CMV infection (reactivation or new infection). The arterial blood pressure is normal in 
most cases. 
Because the possibility of adequately substituting the impaired renal function via periodic 
dialysis, the patients requiring kidney transplantation are usually “healthier” than those 
with liver failure. At the same time, the transplant procedure is less laborious than in the 
case of liver transplantation. These patients may develop late PRES related to calcineurin 
inhibitors administration and usually have high blood pressure, episodes of severe systemic 
infection or rejection. Probably the chronic exposure to the graft endothelium promotes a 
minimal inflammatory response (increased leukocyte trafficking and activation of 
endothelial adhesion molecules). These changes can receive a boost when the immune 
system is stimulated by an infection or an episode of rejection.  
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Patients with allogenic bone marrow transplantation have the highest risk for infection and 
neurotoxicity, because of the aggressive chemotheraphy and total body irradiation (both can 
cause endothelial injury) and because of the potential developement of graft versus host 
disease, requiring high doses of neurotoxic immunosupressants. 
5.1 Calcineurin inhibitors  
Calcineurin inhibitors (i.e. cyclosporine and tacrolimus) are drugs with immunosuppresive 
effects, frequently administered in transplant receivers. They act as blockers of calcineurin, 
which is a T lymphocyte calmodulin-dependent protein. The principal role of calcineurin 
consists of increasing the quantity of interleukin 2 (IL-2) released by the activated T 
lymphocyte. The blockage of this signal stops the clonal expansion of the T lymphocytes, 
thus decreasing the amplitude of the immune response (Gerald 2001). Cyclosporine and 
tacrolimus are frequently administered in transplant recipients, especially in those with 
allogeneic hematopoietic stem cell transplant for the prophylaxis of graft versus host 
disease. Cyclosporine and tacrolimus are absorbed in jejunum, metabolised by P450 
cytocrome and excreted mostly through bile. Their plasma levels are increased by certain 
drugs which are metabolised by the same pathways (e.g. calcium channel blockers, 
macrolides, conasoles, amiodarone, metoclopramide, colchicine, allopurinolum). The drugs 
that are enzyme inducers (e.g. phenytoin, phenobarbital, rifampicin, carbamazepine, 
sulfonylureas) lower the plasma level of cyclosporine and tacrolimus. The optimum blood 
level of cyclosporine is between 250-350 ng/ml in the first 3 months after transplantation, 
with progressive reduction to 100-150 ng/ml after one year, required for minimizing the 
adverse effects. Its potential adverse effects include arterial hypertension, nephrotoxicity 
and neurotoxicity. For tacrolimus, the optimum blood level is 10ng/ml in the first 3 months 
after transplantation, with progressive reduction to 5ng/ml at one year for the same 
rationale as above. Its potential adverse effects are arterial hypertension, nephrotoxicity, 
neurotoxicity and diabetes mellitus. Both drugs cause similar neurotoxicity, which 
particularly occurs in the first months after transplant when the administered doses are 
higher. 
Cyclosporine and tacrolimus are lipophilic molecules which pass the blood-brain barrier, 
sometimes reaching higher concentrations in the corticospinal fluid (CSF) than those present 
in the blood. That is why neurotoxicity can appear early and may not correlate with the 
presence of high blood concentrations. It is commonly accepted that early calcineurin 
inhibitor-induced neurotoxicity occurs within the first 4 weeks since treatment initiation 
(and since transplantation). Their neurotoxicity occurs through various mechanisms, one of 
which is the release of endothelin, which causes intense cerebral vasospasm, sympathetic 
activation and local coagulation disturbances, finally determining vasogenic edema 
affecting predominantly (but not exclusively) the subcortical white matter of the posterior 
regions of the brain. Both cyclosporine and tacrolimus decrease endothelial cell viability 
(Illsinger et al. 2010) and increase endothelial permeability (i.e. endotheliotoxic dysfunction), 
with secondary failure of the cerebral vascular autoregulation and impaired function of the 
blood-brain barrier. Both drugs inhibit P-glycoprotein, which could result in the 
enhancement of the brain distribution of these drugs and thus increased neurotoxicity. 
Factors favouring these alterations induced by cyclosporine and tacrolimus include arterial 
hypertension, concomitant treatment with corticosteroids, hypocholesterolemia, 
hypomagnesemia, concomitant graft versus host disease (as it needs high doses of 
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immunosuppressant therapy) and high aluminium blood levels- occuring especially in the 
patients from developing countries where contaminated dialysis water is still used or in 
those taking over-the-counter aluminium-containing phosphate binders(Bechstein 2000). 
The neurotoxicity induced by calcineurin inhibitors occurs more frequently in liver 
transplanted patients. The neurotoxic effects of cyclosporine and tacrolimus may be divided 
in minor symptoms (mild postural and action tremor of the extremities, distal burning 
paresthesia, somnolence or insomnia, headache, dysarthria, agitation, depression) and major 
symptoms (auditive or visual hallucinations, cortical blindness, akinetic mutism, speech 
apraxia, psychosis, seizures, coma, polineuropathy, myopathy). The exclusion of other 
potential causes (stroke, central nervous system infection, central pontine myelinolisis) is 
mandatory. Following dose modification or swiching to another calcineurin inhibitor there 
is an obvious clinical improvement. Tremor and paresthesias are the most common side 
effects of calcineurin inhibitors, occurring in up to 30% and respectively 11% of the patients. 
These commonly subside when the dose is decreased. Isolated seizures are reported in up to 
5% of patients and may sometimes be associated with hypomagnesemia (nota bene: 
imipenem, cefepime and levofloxacine administration is also associated with seizures). 
Although more severe neurological complications are rare, two CNS syndromes have been 
reported: posterior reversible encephalopathy syndrome (PRES) and a syndrome 
predominantly characterized by motor features of parkinsonism or ataxia. A similar 
syndrome consisting of confusion, tremor and parkinsonism may be caused by 
amphotericin-B. 
PRES is caused by potentially reversible, predominantly vasogenic edema of the white 
matter, with a predilection to the brain regions supplied by the posterior arteries(Wijdicks 
2001).  
PRES can manifest with seizures, disturbed vision, headache and altered mental status. 
Severe hypertension is sometimes present, but usually the mean arterial pressure is normal. 
Because acutely raised blood pressure is found in many PRES patients, it is sometimes 
considered to be an important causal factor. On the other hand, patients with normal blood 
pressure may also develop PRES. Perhaps, therefore, the raised blood pressure is required to 
sustain cerebral blood flow and is reactive rather than a cause. The symptoms usually 
develop quite quickly over a few hours, reaching their worst in 12 to 48 hours since onset. 
Confusion and altered mental status are very frequent findings and may hide other 
symptoms such as disturbed vision and nausea. Patients can be confused, lethargic with 
slowed motor responses or deeply stuporous. As mentioned, seizures, including non-
convulsive status epilepticus, may occur in those with PRES.Differentiating altered mental 
status from non-convulsive status epilepticus on clinical grounds only may be difficult. 
Using EEG monitoring in all patients with altered mental status can help detecting non-
convulsive electroencephalographic seizures. PRES patients with status epilepticus show 
rhythmic delta and sharp waves, mostly in the parieto-occipital and temporal regions. The 
EEG abnormalities resolve along with clinical improvement(Cruz-Martinez et Gilmore 
2002). Visual disturbances occur frequently due to the involvement of the occipital lobe. 
PRES patients may experience not only cortical blindness or homonymous hemianopsia, but 
also blurred vision, visual neglect and visual hallucinations. Headache, usually bilateral and 
dull in nature, commonly occurs in PRES. Tremor of the extremities is a minor but very 
important sign, because most of the patients with altered consciousness due to calcineurin 
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inhibitor neurotoxicity have this sign, which is not so often present when other causes are 
involved. Other clinical features of PRES include nausea and vomiting. These occur less 
frequently. The tendon reflexes are often brisk but symmetrical. Hemiparesis, Babinski’s 
sign and brainstem features may occur occasionally. 
 
 
 
 
Fig. 1. PRES in a 17-year-old male who developed headache, seizures, visual disturbances 
and altered mental status 14 days after cadaveric renal transplant for glomerulonephritis-
related chronic renal failure. He was treated for pneumonia just before toxicity occurred. 
The MR imaging was obtained 4 days after the onset of PRES. (A) FLAIR sequences showing 
bilateral frontal and occipital hyperintensity, translating vasogenic edema. (B) Diffusion 
weighted imaging showing isointensity of the affected areas (i.e. no cytotoxic edema). (C) 
Follow-up FLAIR sequences obtained one month later show resolution of the vasogenic 
edema. 
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The CSF may be normal or show slightly raised protein level.  
Brain imagistic studies (CT or preferably MRI) are required. The common neuroradiological 
abnormalities comprise of the subcortical white matter hyperintensities typically bilaterally, 
nonenhanced and involving mainly the posterior lobes-parietal and/or occipital(Bartynsky 
et al. 2008). Involvement of the anterior brain (frontal lobes, along the superior frontal 
sulcus), cerebellum, and brain stem may also be observed. A typical PRES pattern mostly 
spares the paramedian occipital structures below the sulcus calcarinus. Although PRES is 
often thought to be a leukoencephalopathy, the cortex and deep gray mater can often be 
involved. 
SYNDROME PARTICULAR CHARACTERISTICS 
Posterior circulation stroke - "top of the 
basilar syndrome”  
 
MRI: hyperintensity on DWI images and 
low signal on ADC map; involvement of 
calcarine and paramedian areas 
Primary CNS vasculitis Insidious onset 
Abnormal CSF, with inflammatory changes 
MRI: multiple infarcts, of different ages 
Reversible cerebral vasoconstriction 
syndrome 
Severe headache (thunderclap headache) 
Progression of symptoms in days, not hours 
Angiography: multiple segmental stenoses, 
reversible after few weeks 
Viral Encephalitis- (herpetic) Systemic inflammation signs: fever, blood 
tests, inflammatory CSF changes 
Table 2. The differential diagnosis of PRES 
Although the blood levels of cyclosporine and tacrolimus tend not to correlate with PRES 
and normal serum levels do not rule out drug-related neurotoicity, both clinical and 
radiologic findings can resolve as the blood levels of the offending drug are reduced(Singh 
et al. 2000). Therefore the specific therapeutic approach comprises of lowering of the dose or 
discontinuation of the offending drug, which interestingly can be switched with the other 
calcineurin inhibitor without PRES reoccurring. The encephalopathy is almost always 
reversible but it may not resolve until several weeks after the drug has been stopped. There 
are reports of a potential protective effect of soya bean oil administration (Kentaro et al. 
2007). The lipids contained by this oil may impair the passage of the calcineurin inhibitors 
through the blood-brain barrier, and therefore diminish their accumulation in the central 
nervous system. Symptomatic treatment is also required and should be adapted to each 
case. The minor symptoms related to calcineurin inhibitors neurotoxicity are usually self-
limited and responsive to symptomatic drugs. However, refractory headache leading to 
change of the immunosuppressive drug has been reported. When facing major symptoms 
the usual therapeutic approach is changing the immunosuppressive treatment: either 
substituting calcineurin inhibitor with a non-calcineurin inhibitor (e.g. sirolimus, 
mycophenolate mofetil) or changing the calcineurin inhibitors between each other -
cyclosporine with tacrolimus or tacrolimus with cyclosporine (Guarino et al. 2006). 
Syndrome-specific treatments are mandatory. These include administration of cerebral 
depletive drugs and administration of antiepileptic drugs adapted to the type of seizures 
according to the local guidelines but also adapted to the patient (i.e. lacking either 
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hepatotoxicity or nephrotoxicity and not interfering with the patient’s immunosuppressant 
drugs). Since it does not induce hepatic metabolism of cyclosporine or tacrolimus and can be 
given either orally or intravenously in the absence of liver dysfunction valproic acid may be 
optimal for treatment of seizures. The antiepileptic treatment may be stopped after about 6 
months, unless the seizures reappear. Administration of anxiolytics (for agitation) or 
neuroleptics (for psychotic episodes) may sometimes be required. 
5.2 Corticosteroids  
Corticosteroids prevent interleukin IL–1 and IL-6 production by macrophages and inhibit all 
stages of T-cell activation. In transplanted patients, they are commonly used for the 
induction and maintenance of immunosuppression and for the treatment of acute rejection. 
Corticosteroid administration may cause insomnia, irritability, impaired concentration, and 
mood changes, and sometimes they may even cause psychotic episodes. The treatment of 
corticosteroid-related neurological side effects consists of lowering the dose and 
administering antipsychotic agents. 
5.3 Biologic agents 
The biologic agents include polyclonal and monoclonal antibodies with 
immunomodulatory/immunosuppressive effects. They are used for the induction of 
immunosupresion and for the treatment of graft rejection.  
The polyclonal antibodies (e.g. antithymocyte globulins) are produced by injecting animals 
with human lymphoid cells, then harvesting and purifying the resultant antibody. 
Polyclonal antibodies induce lysis of lymphocytes and mask the lymphoid cell-surface 
receptors. The available pharmaceutical preparations include horse antithymocyte globulin 
(ATGAM) and rabbit antithymocyte globulin (Thymoglobulin). These agents are used for 
immunosupresion induction and treatment of acute graft rejection. Adverse effects include 
fever, chills, thrombocytopenia, leukopenia, hemolysis, respiratory distress, serum sickness, 
and anaphylaxis. Some adverse effects are ameliorated with steroids, acetaminophen, and 
diphenhydramine. 
The monoclonal antibodies used in transplanted patients include monoclonal anti-CD3 
antibody (i.e. muromonab-CD3), monoclonoal anti-CD25 antibody (i.e.basiliximab and 
daclizumab), monoclonal anti-CD20 antibody (i.e. rituximab). Except for muromonab their 
administration in transplanted patients is associated with a very low prevalence of 
neurologic adverse effects.  
Muromonab-CD3 (Orthoklone OKT3) is a murine monoclonal antibody directed to the CD3 
portion of the T-cell receptor. It blocks T-cell function and has limited reactions with other 
tissues or cells. This agent is used for induction and acute rejection (primary treatment or 
steroid-resistant). Its adverse effects include cytokine release syndrome (fever, dyspnea, 
wheezing, headache, hypotension, diarrhea, vomiting, nausea, tremor, generalized 
weakness) and pulmonary edema, usually following the first few doses. Sometimes patients 
experience "shock-like" reactions, which may include cardiovascular and central nervous 
system manifestations. All patients must be carefully evaluated for excessive fluid retention 
and hypertension before the initiation of Muromonab therapy. Close monitoring for neuro-
psychiatric symptoms must be observed during the first 24 hours following the first 
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injection. Patients who may be at greater risk for CNS adverse events include those with 
history of seizures, with cerebrovascular disease, head trauma, uraemia, or who are 
receiving a medication concomitantly that may affect the central nervous system. 
Premedication with steroids (first 2 doses only), acetaminophen, and diphenhydramine 
avoids cytokine release syndrome. The possible neuro-psychiatric events include headache, 
seizures, aseptic meningitis, encephalopathy and cerebral edema/herniation. Seizures, 
which have been occasionally accompanied by cardiorespiratory arrest, have occurred 
independently or in conjunction with any of the neurologic syndromes described below. 
Patients predisposed to seizures are those with the following conditions: uraemia, fever, 
infection, fluid overload, hypertension, hypoglycaemia, history of seizures, and electrolyte 
imbalances. Symptoms of aseptic meningitis include fever, headache, stiff neck and 
photophobia. The cerebrospinal fluid shows leucocytosis, elevated protein and normal or 
decreased glucose, with negative viral, bacterial and fungal cultures. Most patients with 
aseptic meningitis have a benign course, but infectious meningitis must be taken into 
account in the differential diagnosis of an immunosuppressed transplant patient with any 
signs or symptoms of meningitis. Manifestations of encephalopathy may include impaired 
cognition, confusion, altered mental status, auditory/visual hallucinations, psychosis 
(delirium, paranoia), mood changes (mania, agitation), hyperreflexia, myoclonus, tremor, 
asterixis, involuntary movements, major motor seizures, lethargy/stupor/coma and diffuse 
weakness. All these side effects are usually reversible.  
6. Rejection encephalopathy 
Rejection Encephalopathy is a pathogenic entity seen in patients with systemic features of 
acute graft rejection. Commonly the symptoms appear in the first 3 months post 
transplantation. The presumed pathology is cytokine production secondary to the rejection 
process. The clinical picture includes headache, confusion, seizures, and papilledema. The 
lumbar puncture reveals increased CSF opening pressure and the cerebral CT/MRI reveals 
diffuse cerebral edema. The EEG shows diffuse or focal rhythm slowing. The overall 
prognosis is good, with rapid and complete recovery after the immunosuppressive 
treatment of the rejection episode. 
7. Graft versus host disease 
Graft versus host disease is a complex complication of allogenic hematopoieic stem cell 
transplantation. It occurs in 40 to 75% of the patients undergoing this procedure. The 
underlying mechanism comprises of donor T cells reaction against host antigens. 
Neurological complications associated with graft versus host disease occur several months 
after the transplantation, in chronic phase of the disease, and typically involve the 
peripheral nervous system, causing polymiositis, myasthenia gravis and peripheral 
neuropathies compatible with acute Guillain-Barre syndrome or chronic idiopathic 
demyelinating polyneuropathy(Echaniz-Laguna et al. 2004). Brain MRI abnormalities 
comprising mainly of atrophy and white matter lesions are not uncommon in patients with 
chronic graft versus host disease, but their etiopathogeny is difficult to establish since these 
patients associate several factors that may result in brain injury. According to the current 
knowledge, the brain does not express major histocompatibility complex antigens, and 
therefore is expected to be protected from the potential damage induced by autoreactive T 
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cells. However, a few cases of possible central nervous system involvement related to graft 
versus host disease have been reported. These patients presented with subacute 
encephalopathy developing in the setting of systemic involvement. The neuropathological 
examination revealed widespread T-cell infiltrates in the absence of conclusive evidence for 
viral infection. Imagistic features compatible with CNS vasculitis (one case with 
pathological confirmation) were reported to occur in several patients with chronic graft 
versus host disease. The authors that reported the latter series of cases proposed that an 
angeitis-like syndrome involving the CNS may occur as a complication of chronic graft 
versus host disease and may be responsible for the clinical and brain MRI findings 
encountered in some of these patients (Padovan et al. 1999).  
8. Septic encephalopathy  
Sepsis is defined as a known or suspected infection leading to the systemic inflammatory 
response syndrome. Due to the associated immunodepresion sepsis has higher incidence in 
transplanted patients. It frequently presents with delirium and represents perhaps the most 
common causal factor for intensive care unit delirium. Encephalopathy occuring in the 
setting of sepsis may have several causes, being either a direct consequence of sepsis, or 
secondary to various of its associated complications, such as liver or renal failure (resulting 
in metabolic disturbances), or induced by the pharmacologic agents required for its 
treatment. The evolution is usually acute. Though commonly diffuse brain involvement is 
observed, focal brain lesions may also occur. 
The physiopathology of sepsis-associated encephalopathy is complex and involves 
inflammatory and non-inflammatory processes that affect endothelial cells, glial cells and 
neurons and that induce blood-brain barrier breakdown, dysfunction of intracellular 
metabolism, and cell death. The ongoing inflammatory cascade may impair capillary blood 
flow and therefore decrease the brain’s supply of oxygen and essential nutrients and the 
clearance of toxic by-products. Elevated levels of tumour necrosis factor-alpha, interleukin-
1, and other cytokines and chemokines that are released in response to the presence of 
bacterial lipopolysaccharides promote leukocyte–vascular endothelium adhesion and 
induce endothelial damage, sometimes resulting in disseminated intravascular coagulation. 
The endothelial dysfunction may lead to blood-brain barrier disruption with its subsequent 
consequences on brain parenchyma. Peri-microvessel edema impairs the transfer of oxygen, 
nutrients, and metabolites, while increased blood-brain barrier permeability facilitates the 
passage of various neurotoxic factors. The sepsis-related damage of the blood-brain barrier 
is attenuated by glial cells, dexamethasone or nitric oxid syntethase inhibition. 
Mitochondrial dysfunction, oxidative stress, and apoptosis also occur. The formation of 
reactive oxygen species compromises cell function and survival. A major consequence of 
oxidative stress is apoptosis. Neuronal apoptosis can also be secondary to glial cell 
dysfunction. Neurons are also vulnerable to other disturbances that frequently accompany 
sepsis, such as hypoxemia, hyperglycemia, hypoglycemia and consequences of organ 
dysfunction. Liver dysfunction increases plasma levels of ammonium, which interferes with 
neurotransmission. Exposure to lipopolysaccharide causes accumulation of calcium in brain 
cells, impairs synaptic transmission and depresses neuronal excitability. 
Patients with sepsis-associated encephalopathy have altered state of consciousness; they can 
be disoriented, agitated, confused, or delirious but also somnolent, stuporous or comatose. 
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Agitation and somnolence occur alternatively. Confusion and agitation are associated with 
hypoxia; despite hypoxia correction the state of consciousness remains altered, usually 
correlated with septic hypotension. Neurological examination should assess neck stiffness, 
motor responses, muscular strength, plantar and deep tendon reflexes and cranial nerves to 
disclose a focal neurologic sign. Seizures should be considered in the presence of abnormal 
movements or eyelid twitching. In heavily sedated patients, detection of brain dysfunction 
is challenging. Interruption of sedation is necessary for the evaluation of mental status, but 
it is very difficult to discriminate between a sepsis associated encephalopathy and an effect 
of sedative accumulation or withdrawal. In patients who cannot tolerate sedative 
interruption, the diagnosis of brain dysfunction relies on electrophysiology (somatosensory 
evoked potentials, electroencephalogram), serum brain biomarkers (neuron-speciffic 
enolase, S-100b protein) or brain imaging. Routine biochemical tests are mandatory to rule 
out a metabolic disturbance. An EEG may be helpful to detect non-convulsive status 
epilepticus. In sepsis-associated encephalopathy, the electroencephalogram may be normal 
or show excessive theta, predominantly delta, triphasic waves, or burst suppression (the two 
latter patterns are associated with increased mortality). Lumbar puncture should be 
performed if meningitis or encephalitis is suspected. In septic encephalopathy, cerebrospinal 
fluid is usually normal. Brain imaging is indicated in the presence of a focal neurologic sign 
or seizure. In comparison with the CT scan, the MRI allows an accurate exploration of the 
brain, especially of the white matter and blood-brain barrier. MRI can reveal ischemic or 
hemorrhagic lesions, white matter lesions including PRES or leukoencephalopathy related 
to blood-brain barrier breakdown affecting predominately the areas around the Virchow-
Robin spaces, as well as grey matter lesions involving the basal ganglia and thalami. 
Treatment consists of controlling the underlying infection and general supportive measures, 
management of organ failure and metabolic disturbances and avoidance of neurotoxic drugs. 
9. Wernicke’s encephalopathy 
Wernicke’s Encephalopathy is caused by the impairment of thiamine-dependent enzymatic 
activity in the susceptible brain cells. The classical clinical picture comprises of mental status 
changes, ocular motility signs and axial and/or gait ataxia developing acutely or subacutely 
in individuals prone to thiamine (vitamin B1) deficiency (e.g. alcoholics). Atypical clinical 
presentations ranging from unexplained hypothermia to coma may occur, especially in non-
alcoholics. In the majority of cases the clinical picture is completely reversible providing 
adequate parenteral thiamine is promptly supplied (Galvin et al. 2010; Tanasescu 2009; 
Thorarinsson et al. 2011; Thomson et al. 2002). Due to factors related to the underlying 
disease (including increased metabolic requirements, impaired intestinal absorption and 
persistent vomiting) and sometimes to the inadequate diet, transplanted patients have 
increased risk of developing thiamine deficiency and therefore Wernicke’s Encephalopathy 
(Bleggi-Torres et al. 2000; Thomson and Marshall 2006). Moreover, several drugs that may 
be required for the transplanted patients (e.g. 5-fluorouracil, cisplatin, erbulozole, 
ifosfamide metronidazole, antacids, phenytoin, cephalosporins, diuretics and tetracycline) 
may impair thiamine’s absorption or utilization or may increase its elimination, thus 
increasing the risk of developing Wernicke’s Encephalopaty (Kondo et al. 1996; Imtiaz and 
Muzaffar 2010; Hamadani and Awan 2006; Van Belle et al. 1993; Cho et al. 2009). Special 
attention should be paid that those on total parenteral nutrition receive adequate amounts of 
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thiamine. In marginally thiamine deficient patients, the administration of high doses of 
intravenous glucose solution may precipitate the developement of Wernicke’s 
Encephalopathy. Iatrogenic hyperalimentation without adequate thiamine supplementation 
may also precipitate it (Serra et al. 2007; Watson et al. 1981; Sechi and Serra 2007). The 
diagnosis is supported by the presence of characteristic imagistic findings (i.e. symmetrical 
periaqueductal and periventricular gray matter signal changes on brain MRI translating 
cytotoxic and subsequently vasogenic edema and blood brain barrier disruption) and by the 
identification of low thiamine blood levels. However, since parenteral thiamine 
administration is cheap, has virtually no contraindications (except for prior allergic 
reactions) and might be a life saving intervention, its administration should be started on 
clinical grounds only. The presence of concomitant hypomagnesaemia should be searched 
for and corrected. The 2010 EFNS guideline recommends that 200 miligrams of thiamine 
hydrochloride diluted in 100 millilitres of normal saline or glucose solution should be 
administered intravenously, thrice a day, until there is no further clinical improvement and 
advocates the maintenance of a low threshold for thiamine administration and a high index 
of suspicion for Wernicke’s Encephalopathy (Galvin et al. 2010; Tanasescu 2009; 
Thorarinsson et al. 2011; Thomson et al. 2002). 
10. Posttransplantation opportunistic infection involving the CNS  
The incidence of bacterial, fungal, viral and parasitic opportunistic infections is high in 
transplant recipients, especially in those with persistent neutropenia. The prophylactic use 
of broad spectrum antibiotics increases the risk of fungal infections (e.g. various Candida 
or Aspergillus species). Considering the poor prognosis of these infections prophylactic 
approaches are justified. The identification of the pathogen may sometimes be difficult 
and the treatment should be empirically started prior to the identification of the causative 
organism. Though the detailed discussion of the opportunistic infections involving the 
CNS is above the objective of the present chapter, several important aspects are detailed 
bellow. 
Encephalitis caused by Listeria, Toxoplasma, Varicella Zoster virus, Cytomegalovirus and 
Cryptococcus may present with clinical and paraclinical findings similar to that of 
posttransplantation encephalopathies of other causes. In the cronic posttransplant period 
JC virus activation resulting in progressive multifocal leucoencephalopathy (PML) may 
also occur. Viral CNS oportunistic infections are most likely caused by herpes group 
viruses. Adenoviruses are also frequently involved. Routine prophylaxis with acyclovir 
has been reported to significantly reduce the incidence of herpes simplex type I, Varicella 
Zoster virus and Cytomegaovirus infections in transplanted patients(Shanahan et al. 
2009). Human herpesvirus-6 has been reported to cause limbic encephalitis, commonly 
responsive to gancyclovir or foscarnet, in several transplant recipients. Septic Aspergillus 
brain embolism may be encountered, being reported to account for 15% of the 
neurological complications observed at necropsy in hematopoietic stem cells transplanted 
patients. 
The brain MRI reveals multiple lesions preferentially involving the cerebral hemispheres, 
basal ganglia and corpus callosum. The microbiological isolation of the organism is 
especially difficult, the prognosis is poor and treatment (e.g. voriconazole and surgical 
management) should be started as soon as possible (Schwartz et al. 2005). CNS 
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toxoplasmosis (i.e. infection with Toxoplasma gondii) is the most frequent parasitic CNS 
infection occurring in transplanted patients. The clinical picture comprises of various 
degrees of mental status changes associated or not with the presence of focal signs. The 
brain MRI reveals multiple mass lesions, with different characteristics than those seen in 
AIDS-related toxoplasmosis, because in transplant patients contrast enhancement and 
haemorrhage are only rarely encountered(Portegies et al. 2004). Toxoplasma gondii DNA 
may be identified in the CSF of these patients by various tehniques of polymerase chain 
reaction. Though it does not completely eliminate the risk of developing CNS 
toxoplasmosis, the prophylactic administration of trimethoprim/sulfamethoxazole should 
be considered in transplanted patients. Rarely Listeria monocytogenes, Mycobacterium 
tuberculosis and Cryptococcus neoformans may cause meningitis in transplanted patients. 
Brain abscesses caused by Nocardia asteroides, Mucorales or Candida species have been 
reported to occur in transplanted patients (Singh and Husain 2000). 
11. Conclusions 
Transplantation medicine is a constantly changing field. PTE is a common neurologic 
complication with a broad spectrum of causes and presentations. Knowledge of all the 
potential etiologies and of the particularities of transplanted patients are a sine qua non 
condition for the optimal management of these patients. 
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